# Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients

> **NCT01394835** · PHASE2 · UNKNOWN · sponsor: **Rabin Medical Center** · enrollment: 40 (estimated)

## Conditions studied

- Lung Transplantation
- Bronchiolitis Obliterable Syndrome

## Interventions

- **DRUG:** Alpha -1 Antitrypsin
- **DRUG:** Alpha-1 Antitrypsin
- **DRUG:** AAT

## Key facts

- **NCT ID:** NCT01394835
- **Lead sponsor:** Rabin Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-09
- **Primary completion:** 2012-09
- **Final completion:** 2013-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2011-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01394835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01394835, "Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01394835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*